home / stock / drug / drug quote
Last: | $0.99 |
---|---|
Change Percent: | 2.48% |
Open: | $1.02 |
Close: | $0.99 |
High: | $1.06 |
Low: | $0.98 |
Volume: | 24,368 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.99 | $1.02 | $0.99 | $1.06 | $0.98 | 24,368 | 05-03-2024 |
$1.0459 | $1.01 | $1.0459 | $1.05 | $0.9977 | 35,576 | 05-02-2024 |
$1.04 | $0.96 | $1.04 | $1.13 | $0.96 | 46,245 | 05-01-2024 |
$0.965 | $1.09 | $0.965 | $1.126 | $0.93 | 54,092 | 04-30-2024 |
$1.085 | $1.13 | $1.085 | $1.13 | $1.07 | 11,184 | 04-29-2024 |
$1.1 | $1.1006 | $1.1 | $1.13 | $1.05 | 6,530 | 04-26-2024 |
$1.09 | $1.1 | $1.09 | $1.1099 | $1.08 | 13,078 | 04-25-2024 |
$1.09 | $1.13 | $1.09 | $1.1966 | $1.09 | 3,222 | 04-24-2024 |
$1.12 | $1.1275 | $1.12 | $1.195 | $1.11 | 3,499 | 04-23-2024 |
$1.12 | $1.11 | $1.12 | $1.23 | $1.11 | 18,088 | 04-22-2024 |
$1.12 | $1.14 | $1.12 | $1.1661 | $1.11 | 5,974 | 04-19-2024 |
$1.18 | $1.19 | $1.18 | $1.2099 | $1.12 | 6,723 | 04-18-2024 |
$1.14 | $1.11 | $1.14 | $1.22 | $1.11 | 18,115 | 04-17-2024 |
$1.14 | $1.3206 | $1.14 | $1.3206 | $1.13 | 13,043 | 04-16-2024 |
$1.23 | $1.3 | $1.23 | $1.3 | $1.2 | 2,338 | 04-15-2024 |
$1.27 | $1.27 | $1.27 | $1.29 | $1.2001 | 11,268 | 04-12-2024 |
$1.2599 | $1.25 | $1.2599 | $1.28 | $1.2 | 20,455 | 04-11-2024 |
$1.22 | $1.2 | $1.22 | $1.2899 | $1.2 | 2,787 | 04-10-2024 |
$1.28 | $1.2 | $1.28 | $1.28 | $1.2 | 13,499 | 04-09-2024 |
$1.21 | $1.22 | $1.21 | $1.29 | $1.2 | 6,499 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Bright Minds Biosciences Inc. Company Name:
DRUG Stock Symbol:
NASDAQ Market:
Algoma Steel Group Inc. (ASTL) is expected to report for Q3 2024 CTS Corporation (CTS) is expected to report for Q4 2023 Xylem Inc. New (XYL) is expected to report $0.96 for Q4 2023 TIM S.A. American Depositary Shares (Each representing 5) (TIMB) is expected to report for Q4 2023 ...
Bright Minds Biosciences Inc. (DRUG) is expected to report for quarter end 2023-12-31
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD A decade after it was founded as a wholly-owned ...